pf-04457845
Small moleculeexperimental
Clinical trial activity
10 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00836082)
Timeline
Indications
Mechanism of action
- Fatty-acid amide hydrolase 2INHIBITOR
FAAH2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- n-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide
- pf04457845
- pf 04457845
- pf-04457845
- pf-04457845
- pf-04457845
- pf-04457845
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03386487 | Phase 2 | Mar 31, 2018 | Columbia University, Johns Hopkins University, Medical University of South Carolina, National Institute on Drug Abuse (NIDA), Yale University |
| NCT02216097 | Phase 2 | Oct 1, 2014 | Pfizer |
| NCT02134080 | Phase 2 | May 1, 2014 | Tourette Association of America, Yale University |
| NCT01618656 | Phase 2 | Jun 1, 2012 | National Institute on Drug Abuse (NIDA), Yale University |
| NCT01665573 | Phase 2 | May 1, 2012 | Yale University |
| NCT01092845 | Phase 1 | Apr 1, 2010 | Pfizer |
| NCT01002625 | Phase 1 | Nov 1, 2009 | Pfizer |
| NCT00981357 | Phase 2 | Nov 1, 2009 | Pfizer |
| NCT00918164 | Phase 1 | May 1, 2009 | Pfizer |
| NCT00836082 | Phase 1 | Feb 1, 2009 | Pfizer |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 6 | 2 | 2009 |
| Yale University | Academic/Hospital | 4 | 4 | 1 | 2012 |
| National Institute on Drug Abuse (NIDA) | Government | 2 | 0 | 1 | 2012 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Tourette Association of America | Academic/Hospital | 1 | 0 | 1 | 2014 |
7 organizations
Page 1 / 1